Season’s greetings and warm wishes for a safe and healthy 2021
Dear colleagues, At the start of this year, when we embarked on our 25 years of monitoring celebrations, we knew it was going to be a special 12 months. Little did we know then just how unusual and challenging the year would turn out to be…
Cannabidiol (CBD) is not considered a ‘narcotic drug’ under European law
In November 2020, the European Court of Justice published a judgement stating that cannabidiol extracted from the cannabis plant should not be considered a drug under the 1961 United Nations Single Convention on Narcotic Drugs.
New ESPAD results: teenage drinking and smoking down, but concerns over risky cannabis use and new addictive behaviours
Smoking and drinking among 15–16-year-old school students are showing signs of decline, but there are concerns over potentially risky cannabis use and the challenges posed by new addictive behaviours.
Registration opens for European Drugs Winter and Summer Schools 2021
The EMCDDA and the University Institute of Lisbon (ISCTE-IUL) are pleased to open registration today for two upcoming joint events in 2021: the European Drugs Winter School (EDWS) and the European Drugs Summer School (EDSS) (1)(2).
EMCDDA releases study findings on the impact of COVID-19 on drug markets, use and services in the eastern ENP region
The expansion of contactless drug dealing, the increase in the use of licit drugs and the adaptation of drug treatment protocols during lockdown are among the findings highlighted today in a new EMCDDA report: Impact of
COVID-19 disruption and a strong drug market bring new threats to health and security in Europe
High availability across all drug types, drug production within Europe and highly potent substances are among the concerns addressed today by the EU drugs agency (EMCDDA) in its European Drug Report 2020: Trends and Developments (1).